607 related articles for article (PubMed ID: 33940164)
1. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
2. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
Pradeepkiran JA; Reddy AP; Reddy PH
Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
[TBL] [Abstract][Full Text] [Related]
4. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
6. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
7. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
8. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
Das G; Ghosh S
ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
[TBL] [Abstract][Full Text] [Related]
9. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
11. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
12. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
13. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
14. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.
Wang W; Zhou Q; Jiang T; Li S; Ye J; Zheng J; Wang X; Liu Y; Deng M; Ke D; Wang Q; Wang Y; Wang JZ
Theranostics; 2021; 11(11):5279-5295. PubMed ID: 33859747
[TBL] [Abstract][Full Text] [Related]
15. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
16. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
17. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S; Cowan CM; Mudher A
Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tau-induced neurodegeneration.
Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
[TBL] [Abstract][Full Text] [Related]
20. The role of tau in Alzheimer's disease and related disorders.
Medeiros R; Baglietto-Vargas D; LaFerla FM
CNS Neurosci Ther; 2011 Oct; 17(5):514-24. PubMed ID: 20553310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]